Autolus is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer

Using its broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognise cancer cells, break down their defence mechanisms and eliminate these cells.

Autolus has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumours. Autolus believes its programmed T cell therapies have the potential to be best-in-class and offer cancer patients substantial benefits over the existing standard of care, including the potential for cure in some patients.

Maturing

Martin Pule

Founder of Autolus

“My ambition is to build a substantial company which can deliver CAR T-cell therapies to patients. Most investors were only interested in developing certain assets with a view to sell them on again, but Syncona was different and shared the long-term goal to create a sustainable business around a portfolio of technologies. They have backed this with a £30m investment and ongoing operational and strategic support”